Provided by Tiger Trade Technology Pte. Ltd.

Kodiak Sciences Inc.

98.46
+3.663.86%
Post-market: 98.650.1900+0.19%19:59 EDT
Volume:3.79M
Turnover:376.81M
Market Cap:6.16B
PE:-23.68
High:104.00
Open:95.41
Low:93.95
Close:94.80
52wk High:104.00
52wk Low:10.94
Shares:62.58M
Float Shares:39.01M
Volume Ratio:0.36
T/O Rate:9.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1571
EPS(LYR):-4.3220
ROE:-368.37%
ROA:-60.45%
PB:100.85
PE(LYR):-22.78

Loading ...

Kodiak Sciences Price Target Maintained with a $58.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 17

KPK Seizes Rp6 Billion in Silmy Karim Foreign Residence Permit Extortion Case

Tempo
·
Aug 30

Kodiak Sciences Advances ALTO Phase 3 Trial In Diabetic Eye Disease

TIPRANKS
·
Aug 22

Kodiak Sciences Price Target Maintained with a $58.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 17

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 15

Outlook Therapeutics Q3 Net Loss Narrows Slightly as Costs Drop

Reuters
·
Aug 14

Heart Drug Developer Atrium Therapeutics' Q2 Loss Widens as Expenses Rise

Reuters
·
Aug 14

Ensysce Biosciences Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 14

Kodiak Sciences Q2 Net Income USD -65.643 Million

Reuters
·
Aug 14

Kodiak Sciences Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Kodiak Sciences Q2 EPS $(1.05) Misses $(0.95) Estimate

Benzinga Earnings
·
Aug 14

Kodiak Sciences Q2 FY26 Net Loss Widens to $65.64 Million

Reuters
·
Aug 14

Kodiak Sciences Q2 Operating Income USD -66.838 Million

THOMSON REUTERS
·
Aug 14

Kodiak Sciences Says First Patients Enrolled in Late-Stage Diabetic Eye Disease Trial

MT Newswires Live
·
Aug 11

Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 Alto Trial of Ksi-501 in Patients with Diabetic Macular Edema

THOMSON REUTERS
·
Aug 11

Kodiak Sciences (KOD) Is Up 9.1% After Advancing KSI-101 Phase 3 PEAK Trial Enrollment – Has The Bull Case Changed?

Simply Wall St.
·
Aug 09

Analysts Are Bullish on These Healthcare Stocks: Climb Bio (CLYM), Kodiak Sciences (KOD)

TIPRANKS
·
Aug 07

Kodiak Sciences - Completes Enrollment in First Phase 3 Peak Cohort; Topline Data Expected December 2026

THOMSON REUTERS
·
Aug 06

Berenberg Bank Remains a Buy on Kodal Minerals (KOD)

TIPRANKS
·
Jul 20

Is Kodiak Sciences’ (KOD) Shift Into Russell Growth Indices Reframing Its Core Investment Story?

Simply Wall St.
·
Jul 04